All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Sex-specific impact on clinical outcomes in patients with ET
Bookmark this article
|
A single-center retrospective analysis evaluated sex-specific impact on clinical outcomes in patients with essential thrombocythemia (ET).1 This analysis included 556 adult patients (male, n = 245; female, n = 311) diagnosed with ET between January 2014 and June 2022 in China. Results were published in the Chinese Medical Journal by Chen et al.1 |
| Key learnings1 |
|
Male patients with ET demonstrated higher rates of cardiovascular risk factors (39.3% vs 21.8%; p < 0.001), splenomegaly (50.6% vs 37.3%; p = 0.009), and ≥1 adverse genetic mutations (p = 0.008) compared with female patients. |
|
Male patients were more likely to have SF3B1 (p = 0.008) and ZRSR2 (p = 0.024) mutations, and non-myeloproliferative neoplasm-specific somatic mutations at age >60 years (p = 0.021), contributing to poorer prognostic outcomes. |
|
After adjusting for age at diagnosis, male sex was an independent factor for inferior survival (hazard ratio, 3.773; 95% confidence interval, 1.058–13.454; p = 0.041). Conversely, male sex was not associated with myelofibrosis-free survival (p = 0.124), thrombosis-free survival (p = 0.221), or leukemia-free survival (p = 0.300). |
|
These findings underscore the importance of considering sex differences in the diagnosis, prognosis, and management of patients with ET, and suggest that considering sex as a relevant factor in clinical trial design could lead to more personalized and effective treatment strategies. |
- Chen J, Dong H, Yang L, et al. Sex-specific impact on disease outcome and the mutational landscape in essential thrombocythemia: A retrospective cohort study. Chin Med J. 2024;137(12):1495-1497. DOI: 10.1097/CM9.0000000000003106
Your opinion matters
9 votes - 3 days left ...
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox